Related references
Note: Only part of the references are listed.SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes
Min Zhuo et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2022)
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes A Meta-analysis
Darren K. McGuire et al.
JAMA CARDIOLOGY (2021)
Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury
Min Zhao et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)
Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
Deepak L. Bhatt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Gliflozins for the prevention of stroke in diabetes and cardiorenal diseases A meta-analysis of cardiovascular outcome trials
Li-Min Zhao et al.
MEDICINE (2021)
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis
Hang-Long Li et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial
Hiddo J. L. Heerspink et al.
EUROPEAN HEART JOURNAL (2021)
Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease: A Cohort Study
Samantha T. Harris et al.
DIABETES CARE (2021)
Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients
Shih-Chieh Shao et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Sodium-glucose co-transporter 2 inhibition as a mitochondrial therapy for atrial fibrillation in patients with diabetes?
Salva R. Yurista et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus Insights From the DECLARE-TIMI 58 Trial
Thomas A. Zelniker et al.
CIRCULATION (2020)
Acute Kidney Injury Events in Patients With Type 2 Diaoetes Using SGLT2 Inhibitors versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study
Christie Rampersad et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2020)
Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Clare Arnott et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial
Meg J. Jardine et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)
Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease
Jiahua Li et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2020)
Efficacy of Ertugliflozin on Heart Failure-Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease Results of the VERTIS CV Trial
Francesco Cosentino et al.
CIRCULATION (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups Results From the Randomized CREDENCE Trial
Kenneth W. Mahaffey et al.
CIRCULATION (2019)
Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals
Toshiaki Ohkuma et al.
DIABETOLOGIA (2019)
Burden and Outcomes of Heart Failure Hospitalizations in Adults With Chronic Kidney Disease
Nisha Bansal et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2019)
Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease The EMPA-HEART CardioLink-6 Randomized Clinical Trial
Subodh Verma et al.
CIRCULATION (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data From the CANVAS Program
Brendon L. Neuen et al.
CIRCULATION (2018)
Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers
Claire C. J. Dekkers et al.
DIABETES OBESITY & METABOLISM (2018)
Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials
Vlado Perkovic et al.
LANCET DIABETES & ENDOCRINOLOGY (2018)
Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease
Christoph Wanner et al.
CIRCULATION (2018)
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Diabetic Kidney Disease Challenges, Progress, and Possibilities
Radica Z. Alicic et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis
Girish N. Nadkarni et al.
DIABETES CARE (2017)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Dapagliflozin, SGLT2 Inhibitor, Attenuates Renal Ischemia-Reperfusion Injury (vol 11, e0158810, 2016)
Yoon-Kyung Chang et al.
PLOS ONE (2016)
Prevalence of and Trends in Diabetes Among Adults in the United States, 1988-2012
Andy Menke et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
ESRD and Death after Heart Failure in CKD
Maneesh Sud et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Kidney Disease and Increased Mortality Risk in Type 2 Diabetes
Maryam Afkarian et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
David Moher et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Quantifying heterogeneity in a meta-analysis
JPT Higgins et al.
STATISTICS IN MEDICINE (2002)
Projection of diabetes burden through 2050 - Impact of changing demography and disease prevalence in the US
JP Boyle et al.
DIABETES CARE (2001)
Share Paper
